Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Mann, der ein Lithium-Unternehmen im Wert von 1,2 Milliarden Dollar aufgebaut hat, ist zurück...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 931150 | ISIN: NO0010000045 | Ticker-Symbol: PHS
Frankfurt
13.10.25 | 08:18
4,725 Euro
+5,70 % +0,255
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHOTOCURE ASA Chart 1 Jahr
5-Tage-Chart
PHOTOCURE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
4,5854,69009:32

Aktuelle News zur PHOTOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PHOTOCURE Aktie jetzt für 0€ handeln
22.09.Photocure ASA - Share option grant1
04.08.PHOTOCURE: Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review1
04.08.Photocure ASA: Asieris: Cevira NDA Advances to Second Round of Technical Review-
30.07.Photocure ASA reports Q2 results2
30.07.PHOTOCURE ASA Q2 Profit Retreats1
30.07.Photocure Q2 2025 presentation: Record revenue growth amid strategic expansion7
30.07.Photocure ASA: Results for the second quarter of 2025440OSLO, Norway, July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million)...
► Artikel lesen
30.07.Photocure Q2 2025: Rekordumsatz und strategische Expansion5
22.07.Photocure ASA: Invitation to presentation of second quarter and first half year 2025 financial results1
08.05.Photocure ASA reports Q1 results1
08.05.Photocure Q1 2025 presentation: 7% revenue growth amid strategic expansion initiatives5
08.05.Photocure ASA: Results for the first quarter of 2025951OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million)...
► Artikel lesen
05.05.Photocure ASA: Annual general meeting held1
30.04.Photocure ASA: Invitation to presentation of first quarter 2025 financial results2
29.04.Photocure ASA: Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making2
26.03.Photocure appoints Jane Healy as Vice President and General Manager EMEA745OSLO, Norway, March 26, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA. Ms....
► Artikel lesen
24.03.Photocure: Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer346OSLO, Norway, March 24, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress...
► Artikel lesen
14.03.Photocure: New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence360OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an...
► Artikel lesen
19.02.Photocure ASA: Results for the fourth quarter of 2024440OSLO, Norway, Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million)...
► Artikel lesen
17.02.News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared636OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces an update regarding its ongoing collaboration with Richard Wolf to develop a high-definition...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1